§ Mr. Carter-Jonesasked the Secretary of State for Social Services what new research or other considerations led the Committee on Safety of Medicines to change its decision regarding Depo-Provera; if he will make available any such research information; and if he will make a statement.
§ Mr. Kenneth ClarkeThe Committee on Safety of Medicines considered a very substantial quantity of scientific evidence in formulating its advice to the licensing authority on the product licence application for Depo-Provera, including much unpublished data which are confidential for commercial reasons.
The considerations that may have swayed the minds of individual members when the committee was formulating its collective advice are not known.